Latest news with #DanielPinto
Yahoo
17-07-2025
- Business
- Yahoo
Johnson & Johnson (NYSE:JNJ) Reports Bullish Q2, Full-Year Sales Guidance is Optimistic
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company's full-year revenue guidance of $93.3 billion at the midpoint came in 2.1% above analysts' estimates. Its non-GAAP profit of $2.77 per share was 3.2% above analysts' consensus estimates. Is now the time to buy Johnson & Johnson? Find out in our full research report. Johnson & Johnson (JNJ) Q2 CY2025 Highlights: Revenue: $23.74 billion vs analyst estimates of $22.88 billion (5.8% year-on-year growth, 3.8% beat) Adjusted EPS: $2.77 vs analyst estimates of $2.68 (3.2% beat) The company lifted its revenue guidance for the full year to $93.3 billion at the midpoint from $92 billion, a 1.4% increase Management raised its full-year Adjusted EPS guidance to $10.85 at the midpoint, a 2.4% increase Operating Margin: 27.2%, in line with the same quarter last year Free Cash Flow Margin: 26.1%, up from 20.7% in the same quarter last year Organic Revenue rose 3% year on year (6.7% in the same quarter last year) Market Capitalization: $373.4 billion NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. 'We are thrilled to have Daniel join Johnson & Johnson's Board of Directors,' said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Company Overview Founded in 1886 and known for its iconic red cross logo, Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops and sells pharmaceuticals, medical devices, and technologies focused on human health and well-being. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Regrettably, Johnson & Johnson's sales grew at a mediocre 6.4% compounded annual growth rate over the last five years. This fell short of our benchmark for the healthcare sector and is a rough starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Johnson & Johnson's recent performance shows its demand has slowed as its annualized revenue growth of 4.9% over the last two years was below its five-year trend. We can dig further into the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Johnson & Johnson's organic revenue averaged 5% year-on-year growth. Because this number aligns with its normal revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results. This quarter, Johnson & Johnson reported year-on-year revenue growth of 5.8%, and its $23.74 billion of revenue exceeded Wall Street's estimates by 3.8%. Looking ahead, sell-side analysts expect revenue to grow 2.9% over the next 12 months, a slight deceleration versus the last two years. This projection doesn't excite us and implies its products and services will see some demand headwinds. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Johnson & Johnson has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 28.1%. Looking at the trend in its profitability, Johnson & Johnson's operating margin decreased by 14 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 2.8 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. In Q2, Johnson & Johnson generated an operating margin profit margin of 27.2%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Johnson & Johnson's unimpressive 4.6% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Johnson & Johnson reported EPS at $2.77, down from $2.82 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 3.2%. Over the next 12 months, Wall Street expects Johnson & Johnson's full-year EPS of $10 to grow 6.6%. Key Takeaways from Johnson & Johnson's Q2 Results We enjoyed seeing Johnson & Johnson beat analysts' revenue expectations this quarter. We were also glad its full-year revenue guidance exceeded Wall Street's estimates. Zooming out, we think this quarter featured some important positives. The stock traded up 2.2% to $158.61 immediately after reporting. Sure, Johnson & Johnson had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Health
- Yahoo
Johnson & Johnson announces new Phase 1b data on bleximenib
Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia harboring KMT2A gene rearrangements or NPM1 gene mutations. The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML. The results were featured in an oral presentation at the 2025 European Hematology Association Congress. Even though AML is the most common type of acute leukemia in adults, it has the lowest survival rate and is associated with poor patient outcomes, despite treatment advances to date – especially for patients with KMT2Ar and NPM1m. The Phase 1b dose-finding study evaluated 125 patients with relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML who harbored KMT2Ar or NPM1m. Bleximenib in combination with VEN + AZA was evaluated across multiple dose levels without step-up dosing. Of the 85 relapsed or refractory patients, 36 percent received one, 42 percent received two and 12 percent received three lines of prior treatment; 47 percent had previously been treated with venetoclax. The bleximenib data at 100 mg twice a day in combination with VEN + AZA showed higher efficacy and a similar safety profile in comparison to other dose levels. At the recommended Phase 2 dose, patients with relapsed or refractory AML achieved an overall response rate of 82 percent and a composite complete response rate of 59 percent. The newly diagnosed, intensive chemo-ineligible patient population showed an ORR of 90 percent and a cCR rate of 75 percent. Safety analysis of the study population showed a profile comparable among dose groups, genetic subtypes and disease settings. At the RP2D in combination with VEN+AZA, differentiation syndrome events were reported in two of 49 patients. Bleximenib safety data continued to support a lack of QTc prolongation signal, with no events of Grade 3 or higher and only three Grade 1 events at the RP2D. The most common all-grade treatment-emergent adverse events were nausea, thrombocytopenia, neutropenia and anemia. The most common Grade 3 or higher TEAEs were thrombocytopenia, neutropenia, and anemia. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on JNJ: Disclaimer & DisclosureReport an Issue RFK Jr. names eight members to vaccine panel, WSJ reports RFK Jr. names new CDC vaccine advisory panel picks, STAT reports Johnson & Johnson reports results from Phase 3b APEX study on TREMFYA Johnson & Johnson Elects Daniel Pinto to Board Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Yahoo
10-06-2025
- Business
- Yahoo
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
NEW BRUNSWICK, N.J., June 10, 2025--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare innovation for patients." "I've long admired Johnson & Johnson's continued investment in scientific innovation and its commitment to improving health outcomes for patients facing the most challenging diseases," said Daniel Pinto. "It's an honor to join Johnson & Johnson's board of directors and serve alongside board members who are dedicated to improving the health and well-being of communities around the world." About Daniel Pinto Mr. Pinto is a prominent business leader with more than three decades of financial expertise helming critical leadership roles within JPMorganChase, one of the world's preeminent global financial services firms, where he currently serves as President and as a member of the Company's Operating Committee. Mr. Pinto has spent his career at JPMorganChase and its predecessor companies. He began as a financial analyst and foreign exchange trader at Manufacturers Hanover in 1983 in Buenos Aires. In 1992, he was appointed head of Sales for Chemical Bank and, shortly after, became head trader and Treasurer of Chemical Bank in Mexico. Daniel moved to London in 1996 to oversee local markets in Eastern Europe, the Middle East, Africa and Asia for Chase Manhattan, later taking charge of the markets side of the firm's emerging-market business. In early 2006, Mr. Pinto was made global head of Emerging Markets, later expanding his remit to include Global Credit Trading & Syndicate and Global Fixed Income for the Investment Bank. He was made co-CEO of the Corporate & Investment Bank in 2012 and became sole CEO in 2014. In January 2018, he was named Co-President and Chief Operating Officer of JPMorganChase to work closely with the CEO and the Board to identify and pursue critical firmwide opportunities. He became sole President and COO in January 2022. In January 2025, he announced that he would retire from the company at the end of 2026. He retains the role of President until June 30th, 2025, and will then serve as Vice Chairman of the company through 2026. Mr. Pinto holds a bachelor's degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires. He is a member of the Board of Directors of the Institute of International Finance. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at View source version on Contacts Media: media-relations@ Investors:investor-relations@ Sign in to access your portfolio
Business Wire
10-06-2025
- Business
- Business Wire
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. 'We are thrilled to have Daniel join Johnson & Johnson's Board of Directors,' said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. 'He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare innovation for patients.' 'I've long admired Johnson & Johnson's continued investment in scientific innovation and its commitment to improving health outcomes for patients facing the most challenging diseases,' said Daniel Pinto. 'It's an honor to join Johnson & Johnson's board of directors and serve alongside board members who are dedicated to improving the health and well-being of communities around the world.' About Daniel Pinto Mr. Pinto is a prominent business leader with more than three decades of financial expertise helming critical leadership roles within JPMorganChase, one of the world's preeminent global financial services firms, where he currently serves as President and as a member of the Company's Operating Committee. Mr. Pinto has spent his career at JPMorganChase and its predecessor companies. He began as a financial analyst and foreign exchange trader at Manufacturers Hanover in 1983 in Buenos Aires. In 1992, he was appointed head of Sales for Chemical Bank and, shortly after, became head trader and Treasurer of Chemical Bank in Mexico. Daniel moved to London in 1996 to oversee local markets in Eastern Europe, the Middle East, Africa and Asia for Chase Manhattan, later taking charge of the markets side of the firm's emerging-market business. In early 2006, Mr. Pinto was made global head of Emerging Markets, later expanding his remit to include Global Credit Trading & Syndicate and Global Fixed Income for the Investment Bank. He was made co-CEO of the Corporate & Investment Bank in 2012 and became sole CEO in 2014. In January 2018, he was named Co-President and Chief Operating Officer of JPMorganChase to work closely with the CEO and the Board to identify and pursue critical firmwide opportunities. He became sole President and COO in January 2022. In January 2025, he announced that he would retire from the company at the end of 2026. He retains the role of President until June 30th, 2025, and will then serve as Vice Chairman of the company through 2026. Mr. Pinto holds a bachelor's degree in Public Accounting and Business Administration from Universidad Nacional de Lomas de Zamora in Buenos Aires. He is a member of the Board of Directors of the Institute of International Finance. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at
Indian Express
01-05-2025
- Indian Express
UK vlogger visits India's cleanest city, compares it to ‘Singapore': ‘A very strange sight for India'
A recent travel video by UK-based vlogger Daniel Pinto is getting attention from both Indian and international audiences, all thanks to his surprising experience in Indore, the cleanest city in India. Pinto admitted he had no idea about the city's reputation before arriving but was immediately struck by how spotless everything was. 'Welcome to India's cleanest city, Indore! I came here with no idea this city held that title, but it definitely felt like it,' he shared, calling it the 'Singapore of India' in his caption. His video offers a glimpse into daily life in Indore, showing pristine roads and well-maintained surroundings. Landing in the city, Pinto couldn't help but express his surprise: 'A very strange sight for India, no offence,' he said, as he walked along garbage-free streets. He went on to highlight some of Indore's innovative cleanliness initiatives, from door-to-door waste collection to a unique garbage café where locals can trade a kilo of plastic waste for a hot meal. 'Indore isn't just clean – it's a city with purpose,' Pinto noted, applauding the city's efforts. 'Most Indian cities can take a page out of Indore's book cause this place looks more like Singapore than it does India.' Watch the video: View this post on Instagram A post shared by Daniel Pinto† | Travel Creator (@ Social media users echoed his sentiments. One commenter praised the garbage café idea, saying, 'Trash in exchange for a meal is such a cool program.' An Indore resident wrote, 'Being citizen of the city, can confirm the city has transformed in the last 7 years in teams of cleanliness.' Another individual commented, 'Its not just rhe city authorities but efforts of each individual for making it clean.' A fourth person commented, 'Most of foreign travelers visit northern plains espcially the cities which is the dirtiest in India. India has 650k villages where 1 billion people live are lot cleaner. NorthEast India is very clean. South India, Central India and Indian Himalayas are lot less dirty.'
